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Introduction: Ovarian cancer ascitic fluid, which contains malignant cells, is usually present in women with an
advanced stage disease. There are currently no effective therapies for the treatment of ovarian cancer ascitic fluid.
We developed a new therapeutic strategy to target expression of the diphtheria toxin fragment A gene in ovarian
tumor cells under the control of H19 regulatory sequences.
Case presentation: A 64-year-old Caucasian woman was diagnosed with a stage IIIc epithelial ovarian cancer. She
suffered from progressive disease, accumulation of malignant ascites that needed to be drained weekly, abdominal
pain, vomiting, anorexia and severe weakness. Infusion of the diphtheria toxin A chain-H19 plasmid into the
peritoneum of our patient resulted in complete resolution of the ascites with minimum adverse events.
Conclusion: On the basis of this preliminary experience, we are currently conducting an extensive Phase I study
on a larger number of patients in order to assess the safety and preliminary efficacy of this novel patient-oriented
treatment approach.
Introduction
H19 is a paternally imprinted, maternally expressed,
oncofetal gene that has no protein product [1]. It is
expressed at substantial levels in several different human
tumor types, but is only marginally or not at all
expressed in normal adult tissues [2,3]. Recent data sug-
gested a role for H19 in promoting cancer progression,
angiogenesis and metastasis [4].
Based on the results from our pre-clinical studies [5],
we applied a tailored transcriptional regulatory sequence
selection approach as a patient oriented DNA-based
therapy. This approach to gene therapy of human cancer
exploits the genetic and epigenetic alterations in cancer
for targeting the expression of toxic genes. As a toxic
gene, we chose the diphtheria toxin A chain (DT-A),
which has suitable properties for achieving efficacious
cancer cell killing [6]. The H19 promoter will drive the
expression of the therapeutic protein, the DT-A chain.
Diphtheria toxin is secreted from Corynebacterium
diphtheriae as a single polypeptide chain containing two
major domains: A chain (amino-terminal, 193 residues),
which carries the active site for adenosine diphosphate
(ADP)-ribosylation of elongation factor-2, and B chain
(carboxyl-terminal, 342 residues), which promotes bind-
ing of toxin to cells and the entry of the A chain into
the cytosolic compartment. The DT-A chain is a strong
inhibitor of protein synthesis that catalyzes the ADP-
ribosylation of diphthamide, a post-translationally modi-
fied histidine residue present in the elongation factor 2
(EF-2) where it catalyzes the transfer of ADP-ribose
from nicotinamide adenine dinucleotide to EF-2, halting
protein synthesis and killing the cell [7]. It should be
noted that cellular uptake of the DT-A protein requires
the B chain of diphtheria toxin, but is not present in the
plasmid or in any normal cell [8-10]. Thus, in the
absence of the DT-B chain, free DT-A cannot be taken
up by neighboring cells. Unintended toxicity to other
cells can be avoided by introducing the DT-A gene
under the control of regulatory sequences of genes dif-
ferentially expressed in tumours [11]. We constructed a
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by the transcriptional regulatory sequences of the H19
gene (DTA-H19).
Here we present evidence that treatment of a human
patient with ovarian carcinoma using the DTA-H19
construct leads to a highly significant suppression of
ascites progression with very limited apparent toxicity
toward the host, indicating that these constructs have a
high therapeutic potential and are very promising candi-
dates for ovarian cancer therapy in humans.
Case presentation
A 64-year-old Caucasian woman was diagnosed in 2002
with a stage IIIc epithelial ovarian cancer (EOC). She
underwent optimal cytoreductive surgery that included
bilateral salpingo-oophorectomy, hysterectomy, omen-
tectomy, appendectomy, sigmoidectomy and partial
s t r i p p i n go ft h ep e r i t o n e u mf r o mt h er i g h td i a p h r a g m .
After six cycles of paclitaxel and carboplatin chemother-
apy, she had no evidence of disease as evaluated by
computed tomography (CT) scan or CA-125 levels.
However, second-look laparoscopy revealed several
small malignant nodules (less than 3 mm each) on the
right diaphragm. Our patient received three courses of
intra-peritoneal cisplatinum followed by four courses of
docetaxel as maintenance treatment.
Two years later the patient experienced an intra-
abdominal recurrence and was treated again with pacli-
taxel/carboplatin doublet. Due to stable disease after six
courses of treatment she further received topotecan for
eight courses followed by gemcitabine, doxil and etopo-
side. Despite this aggressive therapy, the woman suffered
from progressive disease, accumulation of malignant
ascites that needed to be drained weekly, abdominal
pain, vomiting, anorexia and severe weakness.
Cells from our patient’s ascites fluid were isolated for
the detection of H19 RNA by in situ hybridization
analyses (ISH) (Figure 1A) and by reverse transcriptase
polymerase chain reaction (RT-PCR) analysis (Figure
1B). The isolated ascites cells were also positive for CA-
125 expression as was tested by immunohistochemistry
(IHC) analysis (data not shown). Figure 1 shows strong
hybridization signals in the cytoplasm of our patient’s
ascites cells (Figure 1A). In addition, the RT-PCR analy-
sis of RNA isolated from our patient’s ascites cells also
showed high levels of H19 RNA transcript (Figure 1B).
Since almost all available treatment options had been
administrated and high levels of H19 RNA transcripts
were detected, she was offered a compassionate treat-
ment with DTA-H19.
The study protocol was approved by the medical cen-
ter’s local ethics committees, and the ethical committee
of the Israel Ministry of Health. The study was con-
ducted according to the Helsinki Declaration and fol-
lowed the principles of good clinical practice. Our
patient provided written informed consent. Pre-treat-
ment evaluation by positron emission tomography
(PET)/CT showed an intra-peritoneal fluorodeoxyglu-
cose (FDG) uptake without extra-peritoneal spread. An
intra-peritoneal port-a-cath© (Smiths Medical) catheter
was placed via laparoscopy during which extensive peri-
toneal spread of tumor was found especially in the
upper abdomen.
Our patient was treated with weekly intra-peritoneal
instillation of 80 mg of DTA-H19 vector diluted in
2000 cc NaCl 0.9%, and injected at a rate of 10 cc per
minute (approximately 0.4 mg plasmid per minute).
During the first hour after the treatment, our patient
suffered from nausea, vomiting, fever and chills: blood,
urine and ascetic fluid cultures were all negative for
bacterial infection. Thus, in the next cycles she was
pre-medicated with paracetamol, H2 blocker and anti-
emetics and did not experience any further toxicities
except for mild nausea.
Figure 1 The level of H19 transcript in RNA isolated from cells of ascites fluid of a woman patient, determined by RT-PCR or by ISH.
(A) 40× magnification of H19 transcripts in the isolated ascites cells determined by ISH analysis. The positive stained cells are marked by black
arrows. (B) The H19 transcript in RNA extracted from ascites cells determined by RT-PCR analysis. M: 100 bp ladder, line 1 and 2 are the GADPH
and H19 transcripts, respectively. The sizes of the GAPDH internal control and the human H19 PCR products (300 and 270 bp, respectively), are
marked (black arrows).
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plasmid to 108 mg. Since there were no adverse events,
we further increased the dose of the plasmid to 120 and
140 mg during weeks five to six and week seven, respec-
tively (Table 1). Our patient was closely monitored for
adverse events during the whole study period. Complete
blood count, serum chemistry (kidney and liver func-
tions) and urine analysis were performed. DT-A DNA
was analyzed in the blood and in urine samples (at dif-
ferent times following the treatment) by quantitative
real time PCR (QPCR) analysis.
Blood and urine were collected before and after the
first three infusion cycles. As shown in Figure 2, two
peaks of plasmid were detected after each treatment at
two and 12 hours in the bloodstream and in the urine at
six and 24 hours following plasmid infusion. The first
peak was much higher than the second one. The plasmid
DNA was still detectable by 48 hours after the infusion.
Ultrasound imaging performed before each treatment
showed a reduction in the ascites volume. After ten
weekly intra-peritoneal plasmid infusions our patient
had complete resolution of her ascites (Figure 3).
Clinically, our patient experienced an excellent
response with improvement in her general condition,
appetite, weight gain and daily activities.
A sample of ascites fluid was collected before treatment
number five and examined for malignant cells. Cells were
isolated from ascites fluid using percoll gradient. Only a
few tumor cells were observed microscopically.
CT and PET-CT scans were performed at six weeks
and 3.5 months after the first treatment, respectively.
Both scans showed that although there were still multi-
ple intra-peritoneal areas of 2-Deoxy-2-[18F]fluoro-D-
Glucose (FDG) uptake indicating the presence of cellular
activity of the tumor, an arrest in disease progression
and disappearance of ascites were noticed.
Discussion
Following investigations of the efficiency, safety and
toxicity of H19 DNA based therapy in animal models
[5], we evaluated this novel intra-peritoneal treatment in
a patient suffering from malignant ascites due to resis-
tant EOC. A sample of ascites fluid containing malig-
nant cells was collected and was submitted to
histological and molecular diagnosis. Our patient was
Table 1 Ovarian cancer compassionate patient treatments summary
Treatment number Plasmid infused (mg) Time between
treatments
AEs*
1-3 80 One week 2 hours after 1st treatment: vomiting once, fever 38.3°c for 3
hours, chill, weakness.
2nd & 3rd treatments: Nausea, vomiting once
4 108 One week Nausea
5-6 120 One week Nausea
7 140 One week Nausea
8-10 120 Two weeks No AEs
*During or immediately after plasmid instillation, patient received medications to control the fever elevation, nausea and vomiting.
Figure 2 Pharmacokinetics of DTA-H19 in blood and urine of
the patient after the first treatment. Blood and urine samples
were collected before and after two, six, 12, 24, 48, 72 hours and
one week from each of the treatments one to three. The urine
samples were transferred into test tubes and frozen at -20°C until
analysis. Blood samples were kept for 10 min at room temperature
and then centrifuged for 10 min at 3500 rpm. The serum was
transferred into a new test tube and kept at -20°C until analysis.
Total DNA was isolated from blood and urine. The DNA samples
were submitted to quantitative real time PCR analysis using specific
probe. Panels A and B show the result for blood and urine samples,
respectively.
Mizrahi et al. Journal of Medical Case Reports 2010, 4:228
http://www.jmedicalcasereports.com/content/4/1/228
Page 3 of 5treated with the DTA-H19 plasmid administered intra-
peritoneally after demonstrating high levels of H19 RNA
in the ascites cells by ISH and RT-PCR analysis (Figure
1). The advantage of the intra-peritoneal treatment over
the systemic treatment is to expose the cancer present
within the peritoneal cavity to higher concentrations of
a drug for more prolonged time periods than those
obtained with systemic drug delivery. Taking into con-
sideration the natural history of ovarian cancer, the ana-
tomical and physiological characteristics of the
peritoneal cavity and liver, direct intra-peritoneal drug
delivery could result in a profound increase in the expo-
sure of the cavity to certain anti-neoplastic drugs, while
reducing systemic exposure and toxic effects [12].
The pharmacokinetics analysis of blood and urine col-
lected before and after each treatment showed that plas-
mid DNA was detectable at two and 12 hours in the
bloodstream and in the urine at six and 24 hours follow-
ing plasmid infusion. The graph pattern shows two peaks
of plasmid DNA in different time lines after infusion
(Figure 2). This can be explained by the fact that some of
the plasmid is transferred to the blood stream from the
peritoneum which might be indicated by the first peak,
and then it is transferred through the lymphatic system
into the venous blood stream [13] which might be repre-
sented by the later second peak in the graph (Figure 2).
The main goal of the treatment was to reduce the
amount of ascites fluid which compromised our patient’s
quality of life. We showed that the intra-peritoneal infu-
sions were well tolerated and devoid of any detectable sys-
temic toxicity related to the toxin vector administration.
The amount of ascites fluid was reduced gradually during
treatments and was completely abolished after treatment
number five (Figure 3) as determined by clinical and ultra-
s o u n de x a m i n a t i o n .I ti si m p o r t a n tt on o t et h a tn od r a i -
nage of ascites fluid was performed until treatment
number ten. We also tried to detect the plasmid in cells
extracted from our patient’s ascites, but three weeks after
Figure 3 Ultrasound image of peritoneal cavity from compassionate patient with ovarian carcinoma treated with intra-peritoneal
injection of the DTA-H19 plasmid. Ultrasound imaging was performed before each treatment to evaluate the amount of ascites fluid in our
patient’s peritoneum. A few representative figures of the imaging before the indicated treatments are presented. Red arrows indicate the limits
around the area of ascites.
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isolated. The rapid reduction of cells in the ascites fluid
m i g h ti n d i c a t et h a tD T Aw a se x p r e s s e df r o mt h eD T A -
H19 vector and caused cell death.
Imaging studies showed that although the ascites dis-
appeared, our patient still had evidence of stable mea-
surable disease. This can be explained by the fact that
the penetration ability of the plasmid to deeper layers of
the tumor is limited. This is in accordance with previous
research in which large tumor masses essentially never
regressed, even after ascites disappearance [14]. The
main problem with regional anti-neoplastic therapy is
probably the limited depth of penetration of drugs
directly into the tumor (or normal tissues) by free-sur-
face diffusion [13]. Keeping the safety of our patient was
our first priority although, we are aware of the fact that
a more efficient delivery approach should be developed.
Conclusions
The novel DTA-H19 treatment achieved complete reso-
lution of ascites and an excellent clinical response in a
patient with end stage EOC resistant to chemotherapy.
After seven months of plasmid therapy, the patient was
still alive, had no ascites and resumed regular daily
activities with an improved quality of life.
On the basis of this study we formed a platform for
the design of an extensive Phase I study on a larger
number of human patients to test the safety of this
treatment.
The results obtained in the present study may repre-
sent the first step in a major breakthrough in the treat-
ment of human OCAF. Data regarding the correlation
between the level of H19 expression and the efficacy of
the treatment should be collected during a Phase I and
II clinical trials which are being planned. Based on the
data collected during these future clinical trials we will
be able to identify responders from non-responders in
advance who are resistant to all known therapies,
thereby avoiding treatment failure coupled with unne-
cessary suffering and cost.
Consent
Written informed consent was obtained from the
patient’s son for publication of this case report and
accompanying images. A copy of the written consent is
available for review by the Editor-in-Chief of this
journal.
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